1. Home
  2. NEXT vs MNKD Comparison

NEXT vs MNKD Comparison

Compare NEXT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

N/A

Current Price

$5.21

Market Cap

1.6B

Sector

Energy

ML Signal

N/A

Logo MannKind Corporation

MNKD

MannKind Corporation

N/A

Current Price

$5.98

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEXT
MNKD
Founded
2010
1991
Country
United States
United States
Employees
N/A
407
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
NEXT
MNKD
Price
$5.21
$5.98
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$9.00
$10.08
AVG Volume (30 Days)
3.7M
2.8M
Earning Date
10-30-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.47
EPS
N/A
0.10
Revenue
N/A
$313,787,000.00
Revenue This Year
N/A
$21.54
Revenue Next Year
N/A
$22.21
P/E Ratio
N/A
$60.37
Revenue Growth
N/A
17.43
52 Week Low
$4.99
$3.38
52 Week High
$12.12
$7.07

Technical Indicators

Market Signals
Indicator
NEXT
MNKD
Relative Strength Index (RSI) 35.05 64.93
Support Level $4.99 $5.59
Resistance Level $6.44 $6.01
Average True Range (ATR) 0.30 0.20
MACD -0.09 0.05
Stochastic Oscillator 13.45 80.36

Price Performance

Historical Comparison
NEXT
MNKD

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Share on Social Networks: